The global pharmaceutical-grade Arginine market has faced a price softness in first half of May xxxx with coordinated pricing strategies from suppliers and subdued demand from downstream sectors shaping the overall market sentiment. The major producers and exporters strategically revised their offers which was influenced by balanced inventories and cautious buying patterns. This was a result of restrained consumption of Arginine across major downstream sectors like pharmaceutical, nutraceutical, dietary supplement and functional food & beverage industries. The buyers have maintained a conservative stance with stock levels well-supported by carryovers from previous production cycles and this resulted in notable price corrections in prominent regional markets such as China, India and Germany.
The Arginine suppliers tried to leverage the strategic price adjustments to secure transactional volumes in a market environment marked by reduced procurement urgency. The downstream demand dynamics were changing as the...
